z-logo
Premium
The potential of the estimands framework for clinical pharmacology trials: Some discussion points
Author(s) -
Ring Arne,
Wolfsegger Martin J.
Publication year - 2020
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14233
Subject(s) - clinical trial , bioequivalence , medicine , clinical pharmacology , guideline , pharmacology , medical physics , intensive care medicine , pharmacokinetics , pathology
The recently finalised and published guideline ICH E9 (R1) introduced a new framework for the statistical analysis of clinical trials, namely that of “estimands”. While the framework was originally developed for the analysis of late‐phase trials, it could also provide a rigorous basis for the analysis of clinical pharmacology trials. We illustrate potential applications on two examples: a multiple dose pharmacology trial and the interpretation of confirmatory bioequivalence (BE) trials according to the current FDA and EMA BE guidelines.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here